IM 156

Drug Profile

IM 156

Alternative Names: IM156

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoMet Therapeutics
  • Class Antineoplastics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase inhibitors; Mitochondrial oxidative phosphorylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Brain cancer; Diffuse large B cell lymphoma; Gastric cancer; Glioblastoma; Lung cancer

Most Recent Events

  • 03 Oct 2017 Phase-I clinical trials in Solid tumours (In the elderly, In adults, Late stage disease) in South Korea (NCT03272256)
  • 03 Oct 2017 Preclinical trials in Diffuse large B cell lymphoma in USA, prior to October 2017
  • 03 Oct 2017 Preclinical trials in Gastric cancer in USA, prior to October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top